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Abstract
Human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) offer great hope for in vitro
modeling of Parkinson’s disease (PD), as well as for designing cell-replacement therapies. To realize these
opportunities, there is an urgent need to develop efficient protocols for the directed differentiation of hESC/iPSC
into dopamine (DA) neurons with the specific characteristics of the cell population lost to PD, i.e., A9-subtype
ventral midbrain DA neurons. Here we use lentiviral vectors to drive the expression of LMX1A, which encodes a
transcription factor critical for ventral midbrain identity, specifically in neural progenitor cells. We show that
clonal lines of hESC engineered to contain one or two copies of this lentiviral vector retain long-term self-
renewing ability and pluripotent differentiation capacity. Greater than 60% of all neurons generated from
LMX1A-engineered hESC were ventral midbrain DA neurons of the A9 subtype, compared with *10% in green
fluorescent protein–engineered controls, as judged by specific marker expression and functional analyses.
Moreover, DA neuron precursors differentiated from LMX1A-engineered hESC were able to survive and dif-
ferentiate when grafted into the brain of adult mice. Finally, we provide evidence that LMX1A overexpression
similarly increases the yield of DA neuron differentiation from human iPSC. Taken together, our data show that
stable genetic engineering of hESC/iPSC with lentiviral vectors driving controlled expression of LMX1A is an
efficient way to generate enriched populations of human A9-subtype ventral midbrain DA neurons, which
should prove useful for modeling PD and may be helpful for designing future cell-replacement strategies.
Introduction
Parkinson’s disease (PD) is an incurable, chronicallyprogressive condition characterized by the continuing
degeneration of dopamine (DA) neurons projecting from
the midbrain substantia nigra to the basal ganglia striatum
(Marsden, 1990). Current symptomatic therapies, consisting
primarily of pharmacological DA replacement, compensate
the movement deficit efficiently over a period of several years,
but are ineffective in alleviating the loss of autonomic and
cognitive abilities. Moreover, current treatments are met with
late complications, which might be due, at least partially, to
neurotoxicity of the drugs.
The localized loss of a specialized neuronal cell popula-
tion, paired with the urgent need for long-term treatment
options, makes cell replacement therapy a promising
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approach to treat PD. Clinical trials involving grafting of
embryonic ventral mesencephalic tissue in PD patients have
provided proof-of-concept for the feasibility of cell therapy in
this disease (Lindvall and Bjo¨rklund, 2004). However, this
approach is not widely applicable owing to the limited
supply of such tissues and to ethical concerns.
Human pluripotent stem cells, such as human embryonic
stem cells (hESC) (Thomson et al., 1998), have great potential
regarding their therapeutic use for PD patients (Lee et al.,
2000; Ying et al., 2003; Nat et al., 2007; Morizane et al., 2008).
More recently, the generation of induced pluripotent stem
cells (iPSC) by ectopic expression of a defined set of factors
(Takahashi et al., 2007; Yu et al., 2007; Aasen et al., 2008;
Lowry et al., 2008; Park et al., 2008b) has enabled the deri-
vation of patient-specific pluripotent cells, providing valu-
able experimental platforms to model human disease (Dimos
et al., 2008; Park et al., 2008a; Ebert et al., 2009; Soldner et al.,
2009; Agarwal et al., 2010) and opening the possibility of
implementing patient-matched cell-therapy applications
(Hanna et al., 2007; Wernig et al., 2008; Raya et al., 2009). In
addition, the possibility of genetically engineering human
pluripotent stem cells to express potentially therapeutic
molecules or to manipulate their differentiation toward a
specific phenotype, which, for example, could be used to
increase survival, differentiation, migration, and function of
their progeny, creates new opportunities for the develop-
ment of restorative treatment for PD patients.
The use of hESC/iPSC-based strategies to treat or model
PD, however, is currently hampered by the lack of efficient
protocols for the directed differentiation of human pluripo-
tent stem cells into DA neurons with the appropriate char-
acteristics of A9-subtype ventral midbrain neurons, the
neuronal cell type lost to PD (for review, see Hwang et al.,
2010). A deeper understanding of DA neuron differentiation,
patterning, and specialization will surely facilitate the gen-
eration of an optimal cell source for cell replacement therapy
and disease modeling for PD. During embryo development,
midbrain DA neurons originate in the most ventral region of
the midbrain and are patterned by local induction through
the activity of signaling molecules such as sonic hedgehog
(SHH), fibroblast growth factor 8 (FGF8), and wingless
(WNT) (for review, see Smidt and Burbach, 2007). As a result
of this, a characteristic region-specific makeup of transcrip-
tion factor expression is established in neural progenitors.
Among them, the LIM homeobox transcription factor 1 alpha
(Lmx1a) is selectively expressed in the proliferating neural
progenitors that give rise to ventral midbrain DA neurons in
the mouse, and has been shown to play crucial roles in de-
termining their fate (Andersson et al., 2006). Moreover,
overexpression of Lmx1a in mouse embryonic stem cells
greatly improved their differentiation toward ventral mid-
brain DA neurons (Andersson et al., 2006; Cai et al., 2009;
Friling et al., 2009), prompting the possibility of using
LMX1A modulation to similarly direct the fate of hESC/
iPSC-derived neurons. In support of this possibility, LMX1A
expression was found to be required for the midbrain DA
neuron differentiation of hESC (Cai et al., 2009). In spite of
these promising pieces of evidence, strategies for increasing
DA neuron differentiation of human neural precursors or
hESC by LMX1A overexpression have been met with limited
success. Thus, transfection of LMX1A-expressing constructs
in human neuroblastoma cell lines did not increase the
numbers of tyrosine hydroxylase (TH)-positive neurons (Cai
et al., 2009). Similarly, retroviral overexpression of LMX1A in
immortalized human midbrain progenitors only resulted in
very marginal increases in DA neuron differentiation (Roy-
bon et al., 2008).
A possible caveat in previous attempts to overexpress
LMX1A in human neural stem cells or hESC could be the low
levels of transfection/transduction achieved in these notori-
ously hard-to-transfect cell lines. In this context, the use of
lentiviral vectors (LVs) (Naldini et al., 1996), to obtain robust
and sustained transgene expression in neural or pluripotent
stem cells (Lois et al., 2002; Pfeifer et al., 2002; Ma et al., 2003;
Consiglio et al., 2004), acquires particular relevance. Indeed,
transduction of hESC-derived neural progenitors with LVs
expressing LMX1A under the control of a constitutive phos-
phoglycerate kinase (PGK) promoter has been recently re-
ported to promote the generation of ventral midbrain DA
neurons (Friling et al., 2009).
In this study, we tested whether hESC/iPSC could be
stably engineered using LVs so that they would overexpress
LMX1A in neural progenitors when prompted to differenti-
ate. We show that hESC/iPSC engineered in this way
maintain their normal growth characteristics and retain their
pluripotent differentiation ability, as judged by in vitro dif-
ferentiation and teratoma formation assays. Notably, the
levels of LMX1A overexpression achieved in neural pro-
genitors differentiated from engineered hESC/iPSC are suf-
ficient to boost the generation of ventral midbrain DA
neurons. Analyses of the phenotypic and physiological
properties of these cells, as well as the ability of grafted cells
to survive and integrate into the striatum of adult mouse
brains, showed that LMX1A-induced DA neurons differen-
tiated from hESC/iPSC are essentially similar to authentic
ventral midbrain DA neurons. To the best of our knowledge,
this is the first demonstration that LVs can be exploited to
stably engineer hESC/iPSC for their directed differentiation
toward specific DA neuron phenotypes, thus making it




The hESC lines (ES[2] and ES[4]) and the iPSC lines used
in these studies have been previously described (Aasen et al.,
2008; Raya et al., 2008, 2009). Human pluripotent stem cells
were cultured on the top of irradiated (55 Gy) human fore-
skin fibroblasts (CCD1112SK; ATCC), seeded at a density of
7· 104 cells/cm2 on 10-cm cell culture dishes coated with
0.1% gelatin (Chemicon, Millipore, Temecula, CA). The hESC
and hiPSC were cultured at 37C and 5% CO2 in hESC me-
dium, consisting of KnockOut DMEM (Invitrogen, Paisley,
UK) supplemented with 20% KnockOut Serum Replacement
(Invitrogen), 0.5% human albumin (Grifols, Barcelona,
Spain), 2 mM GlutaMAX (Invitrogen), 50 lM 2-mercap-
toethanol (Invitrogen), nonessential amino acids (Cambrex,
Walkersville, MD), and 10 ng/ml basic fibroblast growth
factor (bFGF) (Peprotech, Rock Hill, NJ). Medium was
changed every day. Individual hESC and iPSC colonies were
passed by mechanical dissociation using a 150-lm-diameter
plastic pipette (The Stripper; Midatlantic Diagnostics, Mount
Laurel, NJ) and replated every 5–7 days. Karyotyping was
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performed by incubating colonies for 30 min in 2ll/ml
Colcemid (Invitrogen) by the G-banding method. Fifteen
metaphases were analyzed for each line.
Plasmid construction, lentiviral production,
and hESC and iPSC transduction
LMX1A or green fluorescent protein (GFP) expression was
driven by the NESTIN enhancer (NesE) (1,852 bp) and the
basic herpes virus thymidine kinase (HSV tk) promoter ele-
ment (925 bp). This enhancer contains a sufficient cis-element
that recapitulates endogenous NESTIN expression in the
CNS (Lothian and Lendahl, 1997). The cassette containing
the NesE, HSV tk promoter, and Lmx1a cDNA was cloned in
the CSC.cPPT.hCMV.GFP.Wpre LV backbone previously
described (Lie et al., 2005). High-titer vesicular stomatitis
virus (VSV)–pseudotyped LV stocks were produced in 293T
cells by calcium phosphate–mediated transient transfection
of the transfer vector pRRL-SIN-PPT-NesE-Lmx1a-ires-GFP-
WPRE, the late generation packaging construct pMDL, and
the VSV envelope–expressing construct pMD2.G, and puri-
fied by ultracentrifugation as previously described (Con-
siglio et al., 2004). Expression titers, determined using HeLa
cells by FACS analysis, were 5· 108 to 1· 109 transducing
units (TU)/ml with an average HIV-1 p24 concentration of
100 lg/ml. The same day of transduction, 2· 105 hESC
(passage 15) were infected in suspension at multiplicity
of infection (MOI) of 10 with LV.NES.LMX1A.GFP,
LV.NES.GFP, or LV.PGK.GFP in the presence of 6 lg/ml
Polybrene (Sigma, Sigma-Aldrich Co, St. Louis, MO). The
day after transduction, the medium was changed and
transduction efficiency was estimated by FACS analysis for
GFP expression.
DA differentiation of hESC
For neural induction, embryoid bodies (EBs) were gener-
ated from large colony fragments obtained by mechanical
splitting with a finely drawn Pasteur pipette and cultured in
nonadherent dishes for 3–4 days in the presence of hES
medium. At Stage 2, EBs were cultured 10 days in suspen-
sion in N2B27 medium consisting of DMEM/F12 medium
(Invitrogen), Neurobasal medium (Invitrogen), 0.5 · B-27
supplement (Invitrogen), 0.5 · N2 supplement (Invitrogen),
2 mM GlutaMAX (Invitrogen), and penicillin–streptomycin
(Invitrogen). In this stage, N2B27 medium was supple-
mented with 10 ng/ml bFGF, 100 ng/ml FGF8 (Peprotech),
and 100 ng/ml SHH (Invitrogen). Finally, at Stage 3 for DA
neuron maturation, the neural precursors cells (NPCs) were
cocultured with PA6 for 3 weeks in N2B27 medium sup-
plemented with FGF8 and SHH.
In vitro differentiation toward the embryonic
germ layers
Differentiation toward endoderm, mesoderm, and neu-
roectoderm was carried out essentially as described (Raya
et al., 2010).
Teratoma formation in nude mice
Severe combined immunodeficient (SCID) beige mice
(Charles River Laboratories) were used to test the teratoma
induction capacity of hES-LMX1A cells essentially as de-
scribed (Raya et al., 2008). All animal experiments were
conducted following experimental protocols previously ap-
proved by the Institutional Ethics Committee on Experi-
mental Animals, in full compliance with Spanish and
European laws and regulations. In brief, *1–3· 106 hES-
LMX1A cells were injected subcutaneously into the testis of
SCID mice anesthetized with isoflurane. Five to 8 weeks after
injection, teratomas were dissected, fixed overnight in 10%
buffered formalin phosphate, and embedded in paraffin.
RT-PCR analysis
Total mRNA was isolated by guanidinium thiocynate–
phenol–chloroform extraction (TRIzol; Invitrogen) and trea-
ted with DNase I. One microgram was used to synthesize
cDNA by using the SuperScript III Reverse Transcriptase
Synthesis Kit (Invitrogen). Quantitative PCR (qPCR) analysis
was done in triplicate on 50 ng by using Platinum SYBER
Green qPCR SuperMix (Invitrogen) in an ABI Prism 7000
thermocycler (Applied Biosystems). All results were nor-
malized to the average expression of hypoxanthine phos-
phoribosyltransferase (HPRT) and B-2-MICROGLOBULIN.
Results were obtained from three or four technical replicates
of three or four independent biological samples at each data
point. Transcript-specific primers used were as follows: B2M,
5’-GCCGTGTGAACCATGTGACT-3’ and 5’-GCTTACATGT
CTCGATCCCACTT-3’; HPRT, 5’-TATGGACAGGACTGA
ACG TCTTG-3’ and 5’-GCACACAGAGGGCTACAATGTG-
3’; LMX1A, 5’-AGGAAGGCAA GGACCATAAGC-3’ and 5’-
ATGCTCGCCTCTGTTGAGTTG-3’; PAX6, 5’-GCTTCAC
CATGGCAAATAACC-3’ and 5’-GGCAGCATGCAGGAG
TATGA-3’; SOX1, 5’-TACGT TTATTTCAGCAGCCTTAGG-
3’ and 5’-TCCAGGACAAGGAAGGGTGTT-3’; NURR1, 5’-
CGCCTGTAACTCGGCTGAAG-3’ and 5’-CTTGAGGCGAG
GACCCATAC-3’; ALDH1A1, 5’-TGACAAGATCCAGGGC
CGTACAAT-3’ and 5’-TGAGAGGAGTTTGC TCTGCTG
GTT-3’; EN1, 5’-CAGACCCATAATCCTGCATTTCTC-3’
and 5’-TTTGGGA TGTAGGCAAATGGA-3’; OCT4, 5’-GGA
GGAAGCTGACAACAATGAAA-3’ and 5’-GGCCTGCACG
AGGGTTT-3’; NANOG, 5’-ACAACTGGCCGAAGAATA
GCA-3’ and 5’-GGTTCCCAGTCGGGTTCAC-3’; TH, 5’-CCG
AGCTGTGAAGGTGTTTGA-3’ and 5’-CGGGCCGGGTC




DNA extraction, Southern, and integration analysis
DNA isolation was performed with the DNeasy Blood &
Tissue kit (Invitrogen) according to the manufacturer’s
instructions. For Southern analysis, the genomic DNA was
digested overnight with 40 U of PstI restriction enzyme
(New England Biolabs, Ipswich, MA), electrophoresed on a
1% agarose gel, transferred to a neutral nylon membrane
(Hybond-N; Amersham, GE Healthcare Limited, Buckingham-
Shire) by capillary transfer, and hybridized with a GFP di-
goxigenin (DIG)–2’-deoxyuridine 5’-triphosphate–labeled
probe generated by PCR using the PCR DIG Probe Synthesis
Kit (Roche Diagnostics, GmbH, Mannheim, Germany). The
probe was detected by an alkaline phosphatase–conjugated
DIG-Antibody (Roche Diagnostics) using CDP-Star (Sigma-
Aldrich) as a substrate for chemiluminescence. The GFP
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probe was generated using an eGFP template with the
primers GFP-F 5’-CGCACCATCTT CTTCAAGGAC-3’ and
GFP-R 5’-CATGCCGAGAGTGATC CCG-3’.
Quantification of transgene copy number per cell was
analyzed by qPCR using Platinum SYBER Green qPCR Su-
perMix (Invitrogen) in an ABI Prism 7000 thermocycler
(Applied Biosystems, Life Technologies, Paisley, UK). To
determine the number of integrations, primers specific for
the transgene sequence were generated: IRES-F, 5’-TGTGAG
GGCCCGGAAAC-3’ and IRES-R 5’-GGGAAAGACCCC
TAGGAATGC-3’. To quantify the number of cells, B-ACTIN
primers were used: B-ACTIN-F 5’-ATTGGCAATGAGCG
GTTCC-3’ and B-ACTIN-R 5’-ACA GTCTCCACTCACCC
AG GA-3’. To measure the average proviral DNA per
transduced cell, two standard curves were made: one em-
ploying a known amount of the LV (LV.NES.LMX1A.GFP)
using the IRES primers, and a second curve employing a
known number of cells and the B-ACTIN primers. Next, the
average proviral number per cell was estimated by interpo-
lation of the IRES-to-B-ACTIN ratio from each DNA sample
in the two standard curves.
Immunochemistry and cell counts
hESC and iPSC were grown on plastic cover-slide chambers
for immunostaining. Cells were fixed with 4% paraformalde-
hyde and then permeabilized with 0.5% Triton X-100 in Tris-
buffered saline. Cells were then blocked in 0.5% Triton X-100
with 3% donkey serum for 2 hr before incubation with primary
antibody overnight at 4C. The following antibodies were used:
mouse anti-Tra-1-60 (Chemicon; 1:100), mouse anti-Tra-1-81
(Chemicon; 1:100), rabbit anti-Sox2 (Chemicon; 1:500), rabbit
anti-GAD (Chemicon; 1:1,000), mouse anti-HNA (Chemicon;
1:200), rabbit anti-calbindin (Chemicon; 1:1,000), rabbit anti-
Nestin (Chemicon;1:200), rat anti-DAT (Millipore; 1:400,
Hudson, WI), mouse anti-SSEA-4 (MC-813-70, 1:2), and mouse
anti-SSEA-3 (MC-631, 1:2) (from the Developmental Studies
Hybridoma Bank at the University of Iowa), rabbit anti-TH
(Sigma; 1:1,000), rabbit anti-Girk2 (Sigma; 1:40), mouse anti-
ACTA1 (Sigma; 1:400), mouse anti-SMA (Sigma; 1:400), rabbit
anti-a-fetoprotein (1:400), rabbit anti-GFAP (Dako; 1:1,000,
Dako, Denmark), mouse anti-Tuj1, (Covance; 1:500, Emery-
ville, California), mouse anti-Oct-3/4 (Santa Cruz; 1:100), rabbit
anti-Gata4 (Santa Cruz; 1:50), goat anti-Nanog (Everest Biotech;
1:100, Oxford-Shire, UK), goat anti-FoxA2 (R&D Biosystems;
1:100), chicken anti-GFP (AveLabs; 1:200), rabbit anti-5-HT
(Immunostar; 1:2,000), mouse anti-synaptophysin (Millipore;
1:500, Hudson, WI), rabbit anti-DBH (Chemicon; 1:200), and
rabbit anti-Lmx1a (kindly provided by Dr. M.S. German,
University of California, San Francisco Diabetes Center).
Secondary antibodies used were all the Alexa Fluor Series from
Invitrogen (all 1:500). Images were taken using a Leica SP5
confocal microscope. For quantification of stained cells,
300 cells per differentiated aggregate were randomly counted
(average six to eight differentiated aggregates per experiment).
Data points represent the average of at least three independent
experiments.
Transplantation in immunodeficient mice
Twenty 6-week-old SCID beige mice were anesthetized and
stereotaxically injected with 2· 105 cells at Stage 3 in 2ll using
a Hamilton syringe in the striatum. The cells were injected at
1ll/min rate. Mice were sacrificed at 1 month (n= 11) and 5
months (n= 8) after transplantation. Upon sacrifice, animals
were perfused transcardially with paraformaldehyde (4%),
and the brains sectioned at 20lm on a freezing microtome
and stained with antibodies as previously described. Brain
sections were analyzed for the presence of immunoreactive
cells along the entire length of the graft. All animal experi-
ments were conducted following experimental protocols pre-
viously approved by the Institutional Ethics Committee on
Experimental Animals, in full compliance with Spanish and
European laws and regulations.
DA enzyme-linked immunosorbent assay (ELISA)
Levels of DA were quantified using an ELISA kit obtained
from Rocky Mountain Diagnostics (Colorado Springs, CO;
http://www.rmdiagnostics.com) according to the manufac-
turer’s instructions. In brief, after being rinsed in a low-KCl
(4.7 mM) solution, the cells were incubated in 1 ml of a high-
KCl (60 mM) solution for 15 min at 37C. After stimulation
with high potassium, DA was measured by ELISA analysis,
as previously described (Trzaska et al., 2007).
Electrophysiology recordings
Electrophysiology studies were performed using E2
Technology (Aleria Biodevices, Barcelona, Spain). In brief,
the cells are cultured in a plate composed of pairs of wells
connected through a 1-mm-long microchannel, cells are
seeded in the wells, and axons sprout all along the micro-
channel. For recording, one electrode is located in each well.
NPCs were seeded in the wells on the top of PA6; 3 weeks
later, recordings in loose-patch mode were obtained (Mor-
ales et al., 2008).
Statistical analysis
Data were statistically analyzed by Student’s t test using
Microsoft Excel software as indicated.
Results
In vitro differentiation of DA neurons from hESC/iPSC
In a first series of experiments, we used the ES[4] hESC
line previously derived in our laboratory (Raya et al. 2008),
maintained by mechanical passaging on top of feeder layers
of irradiated human foreskin fibroblasts. To promote DA
neuron differentiation, we implemented a three-stage pro-
tocol involving (1) hESC aggregation (via EB formation), (2)
neural induction, and (3) DA neuron maturation using a PA6
feeder-based system (Kawasaki et al., 2002) (Fig. 1a). Speci-
fically, neural induction was carried out by incubating EBs in
suspension for 10 days in a defined medium supplemented
with FGF2, SHH, and FGF8 (Ying et al., 2003; Roy et al., 2006)
(Fig. 1b). After that, in Stage 2, NPCs positive for early neural
markers, such as NESTIN and SOX2, started to become ap-
parent in the dish (Fig. 1c and d). To achieve DA neuron
maturation, NPCs were then treated in Stage 3 with FGF8/
SHH and plated on top of PA6 cells. At this stage and under
these conditions, almost 50% of the cells expressed the neu-
ronal marker TUJ1, of which *50% were of DA lineage as
judged by TH expression (Fig. 1e). In our hands, differenti-
ation of hESC in monolayer (e.g., without EB formation) or in
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the absence of PA6 coculture resulted in poor DA neuron
yield ( < 10% of the differentiated cells were neurons, of
which < 25% were DA neurons; Fig. 1f). Similarly, supple-
mentation with FGF2 during the entire differentiation pro-
tocol resulted in fewer neurons and DA neurons compared
with conditions where FGF2 was withdrawn during Stage 3
(Fig. 1f).
As expected, the expression of SSEA-3 and TRA-1-81,
markers of undifferentiated hESC, dramatically declined
during the differentiation process, so that only 0.1% of the
cells expressed both markers at the end of the protocol, as
judged by flow cytometry (Fig. 1g). We confirmed these re-
sults by real-time quantitative RT-PCR analyses of OCT4
expression, which also showed a marked decrease as dif-
ferentiation proceeded (Fig. 1h). To test whether our differ-
entiation protocol could be applied to other lines of human
pluripotent stem cells with comparable results, we subjected
an additional hESC line {ES[2] (Raya et al., 2008)} and two
FIG. 1. Differentiation protocol implemented for the generation of DA neurons and validation of specific expression of
LMX1A in neural precursor cells. (a) Schematic representation of the different stages for the in vitro differentiation of
pluripotent stem cells toward DA neurons. At Stage 1, EBs are formed by aggregation. At Stage 2, NPCs are obtained
culturing the EBs in suspension with N2B27 medium supplemented with FGF2, FGF8, and SHH. At Stage 3, NPCs are
cocultured with PA6 for 3 weeks and DA neurons are generated. (b) NPCs formed at Stage 2 express the neural precursor
markers NESTIN (c) and SOX2 (d). (e) At Stage 3, some of the TUJ1-positive cells generated coexpress TH. (f) Omitting the EB
generation step or the coculture with PA6 cells results in < 10% of the cells differentiating to neurons, of which*24% are TH-
positive. Better results are obtained with the addition of FGF2 during the coculture with PA6; the number of neurons
generated is 14% and 40% of the neurons stained for TH. With the three-stage protocol implemented in (a), the yield of
neurons generated increases to 48% and the TH-positive neurons to 50%. (g) Flow cytometry analysis shows that, in the
undifferentiated state, 90% of the cells are positive for TRA-1-81 or SSEA-3. This value is reduced to 38% in NPCs and to 10%
at the first week in coculture with PA6. At 3 weeks in coculture with PA6, 99% of the cells are double negative, thus indicating
that mainly all of the cells have entered into the differentiation process. (h) A decrease or inactivation of the expression of the
pluripotency marker OCT4 is found as the differentiation occurs. (i, j) The neural precursor markers PAX6 and SOX1 show
activation in NPCs, and the expression starts to decay at 3 weeks in coculture with PA6. (k) The DA progenitor marker
LMX1A starts to be expressed in NPCs, but reaches the maximum level of expression during coculture with PA6. (l) TH levels
of expression are first detected in NPCs, and its expression is maintained or grows until the end of the protocol. *p< 0.05.
Scale bar = 50 lm. In all experiments, n = 3. Color images available online at www.liebertonline.com/hum
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independent lines of iPSC [KiPS4F#1 and cFA404FiPS4F#1
(Aasen et al., 2008; Raya et al., 2009, respectively)] to the same
protocol and harvested samples at different time points for
analyses of gene expression. The behavior of all four hESC/
iPSC lines was similar in terms of the decrease in OCT4 ex-
pression and the up-regulation of neural and neuronal
markers (Fig. 1h). Specifically, markers of neural precursors
such as PAX6 and SOX1 were found up-regulated in all cell
lines tested, peaking at the end of Stage 2 or the first week of
Stage 3, whereas markers of DA neuron phenotype such as
TH peaked at later time points. The expression of LMX1A,
encoding a key transcription factor for midbrain identity
(Andersson et al., 2006), showed an intermediate profile, with
maximum levels reached between weeks 2 and 3 of Stage 3
(Fig. 1i–l). These results show that we have optimized a
protocol for DA neuron differentiation from human pluri-
potent stem cells that is applicable to both hESC and iPSC,
and that achieves DA neuron differentiation efficiencies in
the range of previously published protocols (for review, see
Hwang et al., 2010). However, and also in agreement with
previous reports (for review, see Hwang et al., 2010), DA
neurons generated with our protocol were not the majority
of the specific subtype lost in PD (i.e., A9-subtype ventral
midbrain DA neurons), as judged by the expression of G
protein–activated inward rectifier potassium channel 2
(GIRK2; encoded by potassium channel, inwardly rectifying,
subfamily j, member 6; KCNJ6) (Inanobe et al., 1999; Mendez
et al., 2005) (see below).
Achieving neural-specific overexpression of LMX1A
Therefore, we next asked whether delivering the ventral
midbrain DA lineage-associated transcription LMX1A to
human pluripotent stem cells could provide appropriate re-
gionalization cues during their differentiation. For this pur-
pose, we generated an LV (LV.NES.LMX1A.GFP; Fig. 2a) in
which LMX1A expression is driven by a neural NESTIN
enhancer, active in neural progenitor cells (Lothian and
Lendahl, 1997) and a minimal TK promoter. The vector also
expressed GFP downstream of an IRES element, to allow
monitoring of the transgenic expression of LMX1A during
the differentiation process. After transduction of hESC with
this LV at an MOI of 50, GFP expression was not observed in
undifferentiated hESC, whereas it could be clearly detected
by epifluorescence microscopy or flow cytometry during
the early steps of neural differentiation (Fig. 2b and c).
In contrast, > 90% of hESC transduced in parallel with
LVs expressing GFP from a constitutive PGK promoter
(LV.PGK.GFP) displayed strong GFP expression in both the
undifferentiated state and during neural differentiation (Fig.
2b and c). The specificity of the LV.NES.LMX1A.GFP con-
struct in hESC undergoing neural differentiation was further
confirmed by testing coimmunolocalization of GFP and
NESTIN (Fig. 2d).
To investigate the effect of LMX1A overexpression during
the differentiation of human pluripotent stem cells, we sub-
jected hESC tranduced with LV.NES.LMX1A.GFP to our
three-stage DA neuron differentiation protocol, and com-
pared the overall yield of neurons and DA neurons with
those of hESC transduced with a control (LV.NES.GFP)
virus. Whereas no overt differences were found in the total
number of neurons in each condition at the end of Stage 3,
hESC overexpressing LMX1A generated a significantly
higher proportion of DA neurons (Fig. 2e). However, the
increased DA neuron differentiation of LV.NES.LM-
X1A.GFP-transduced hESC was progressively lost as cells
were passaged (Fig. 2e), concomitant with a decrease in the
levels of transgenic LMX1A overexpression (Fig. 2f), sug-
gesting silencing of the LV transgenes and/or selection of
untransduced hESC upon passaging.
Generation of hESC clones overexpressing LMX1A
To circumvent the loss of LMX1A expression in bulk-
transduced hESC, we set out to generate clonal lines of
LV.NES.LMX1A.GFP-transduced hESC (hES-LMX1A cells).
As controls, stable cell lines transduced with LV.NES.GFP
were generated (mock-hESC). In order to obtain hESC colo-
nies derived from single cells, 5 days after infection (MOI 10)
cells were trypsinized to single cells and serial dilutions
plated on human feeder fibroblasts in six-well plates. Be-
tween 3 and 6 weeks after plating, colonies of tightly packed
cells with a high nucleus-to-cytoplasm ratio and hESC-like
morphology appeared in those cultures. We picked and ex-
panded nine independent colonies from wells in which only
two to four colonies had grown. The number of lentiviral
integration(s) in each clonal line were first screened by qPCR
on genomic DNA using primers specific to the IRES se-
quence and normalized for b-actin (see Materials and
Methods for details). From the nine clones analyzed, five of
them (clones A, C, G, H, and K) showed no lentiviral inte-
grations, three of them (clones B, L, and I) contained a single
lentiviral integration, and one (clone D) showed two inte-
grations. The accuracy of this PCR-based screen was con-
firmed in selected clones by Southern blot hybridization (Fig.
3a). We selected clones D and L of transgenic hES-LMX1A
cells for a thorough characterization and first tested whether
the LV transduction could support undifferentiated hESC
culture for extended periods of time. After 32 passages, or 8
months in continuous culture, transgenic hES-LMX1A cells
maintained a normal 46-XY karyotype (Fig. 3b and data not
shown) and remained undifferentiated and pluripotent, as
judged by the expression of pluripotency-associated markers
OCT4, NANOG, and SOX2, and surface markers SSEA-3,
SSEA-4, TRA-1-81 (Fig. 3c–e and data not shown), and the
ability to differentiate in vitro into derivatives of the three
main embryonic germ layers (Fig. 3f–h and data not shown).
In addition, injection of clone D hESC into immunocom-
promised mice resulted in complex teratomas containing
derivatives from all three germ layers, further confirming
that transgenic hES-LMX1A cells were pluripotent (Fig. 3i–
k). Overall, these results show that genetic manipulation of
hESC with LVs expressing LMX1A under the control of a
neural NESTIN enhancer does not cause any conspicuous
deleterious effect in their self-renewing or pluripotent dif-
ferentiation abilities.
Effect of neural-specific overexpression of LMX1A
on DA neuron differentiation
Transgenic clones of hES-LMX1A cells showed a robust
overexpression of LMX1A under DA neuron differentiation
conditions, reaching levels of up to 10-fold higher than those
of mock-hESC (Fig. 4a). During the course of DA neuron
differentiation, both hES-LMX1A and mock-hESC showed
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a progressive decline in the expression of pluripotency-
associated genes such as NANOG, until levels were barely
detectable (Fig. 4b). However, the increase in the expression
of genes associated with DA neuron differentiation, such as
nuclear receptor subfamily 4, group a, member 2 [NR4A2, en-
coding nuclear receptor-related 1 (NURR1)], engrailed 1
(EN1), aldehyde dehydrogenase 1 (ALDH1A1), and TH, was
significantly more pronounced in hES-LMX1A cells when
compared with mock-hESC (Fig. 4c–f), suggesting that more
cells were being specified to a DA neuron lineage. We di-
rectly addressed this possibility by analyzing the expression
of relevant markers (Isacson et al., 2003) at various time
points of the differentiation protocol by immunofluorescence
(Fig. 4g–p). As expected, more LMX1A-positive cells were
found in differentiating hES-LMX1A cells in comparison
with mock-hESC at Stage 2 (Fig. 4g and h). Moreover, at the
end of Stage 3, hES-LMX1A cells generated > 25% more DA
neurons than mock-hESC (Fig. 4i and j), as evaluated by
quantifying the number of TH/TUJ1 double-positive cells
(Fig. 4q). Importantly, the majority of DA neurons differen-
tiated from hES-LMX1A cells, but not from mock-hESC,
presented the typical bipolar morphology of mDA neurons,
FIG. 2. Ectopic LMX1A is specifically expressed in neural precursor cells. (a) Schematic representation of the proviral form
of LV.NES.LMX1A.GFP, in which the expression of LMX1A and the reporter GFP is driven by the activation of the NESTIN
enhancer. (b) Bright-field and fluorescent images showing no expression of GFP in the undifferentiated cells infected with
LV.NES.LMX1A.GFP and expression of GFP in NPCs from cells infected with LV.NES.LMX1A.GFP. GFP is present in
undifferentiated and NPCs from cells infected with LV.PGK.GFP. (c) Flow cytometry analysis for GFP. More than 93% of the
cells infected with LV.PGK.GFP present GFP expression in an undifferentiated state and NPCs. Of the cells infected with
LV.NES.LMX1A.GFP, almost none are positive for GFP in the undifferentiated state, but*77% of the NPCs are GFP-positive.
(d) NPCs infected with LV.NES.LMX1A.GFP coexpress NESTIN and GFP. (e) Quantification of the neuronal and dopami-
nergic yield at Stage 3. Cells infected with LV.NES.LMX1A.GFP show in four passages a decrease in the amount of TH-
positive neurons from 70% to 55%, the latter value having been obtained using LV.NES.GFP. The number of neurons
obtained in all the cases is *55%. (f) LMX1A expression is markedly decreased at passage 20 compared with that at passage
16. *p < 0.05. Scale bar = 50lm. In all experiments, n = 3. Color images available online at www.liebertonline.com/hum
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FIG. 3. Generation of hESC clones
overexpressing LMX1A. (a) Southern
blot analysis of clones D, G, and L using
a probe against LMX1A informing about
the lentiviral integration copy number.
Integration results using qPCR confirm
the results obtained in the Southern blot.
(b) The transduced clone D showed
normal karyotype. (c–e) After the infec-
tion, clone D retains the pluripotency
capacity as judged by the expression of
pluripotency markers NANOG, TRA-1-
81, OCT-4, SSEA-3, SOX2, and SSEA-4.
The ability to give rise to the three germ
layers in vitro (f–h) and in vivo (i–k) is
also shown. Scale bar= 50 lm. Color
images available online at www
.liebertonline.com/hum
FIG. 4. LMX1A enhances generation of midbrain DA neurons in hESC. (a) qPCR analysis for relative levels of LMX1A expression
showing overexpression of LMX1A in hES-LMX1A (clone D) compared with mock-hESC. Relative levels of expression of the
pluripotency markerNANOG (b) are similar in both lines. Higher levels ofNURR1 (c),EN1 (d),ALDH1A1 (e), andTH (f) are observed
in hES-LMX1A compared with mock-hESC. (g–w) hESC are differentiated and analyzed at different stages of the DA protocol. (g, h)
Staining for LMX1A at Stage 2 is more prominent in hES-LMX1A than in mock-hESC. Staining at the end of the protocol for TH and
TUJ1 (i, j), TH and GIRK2 (k, l), and TH and DAT (m, n), show a higher number of TH-, GIRK2-, and DAT-positive neurons in hES-
LMX1A as compared with mock-hES. Only hES-LMX1A in Stage 3 present TH-positive neurons with staining of FOXA2 in the
nucleus, a feature typical of mDA neurons but not mock-hES (o, p). (q) Quantification of TUJ1, TH, and GIRK2 expression at the end
of the protocol. The expression of TUJ1 is *55% in both infected lines. Approximately 55% of mock-hESC TUJ1-positive cells
expressed TH, and this amount increased to 80% in hES-LMX1A. The expression of GIRK2, a midbrain DA neuron marker, is
restricted to 20% of the cells from mock-hESC and present in the majority of TH-positive neurons from hES-LMX1A. (r–w) Analyses
for other neuronal subtypes within the culture at the end of the protocol. (r) Some TH-positive neurons are positive for calbindin in
mock-hES, indicating that they are A10 neurons. In contrast, in hES-LMX1A, there is no costaining for TH and calbindin (s). (t, u)
Absence of DBH-positive neurons within the culture. (v, w) Absence of 5-HT-positive neurons within the culture. (x) DA release
analysis exhibiting release of DA after treatment with high KCl only in the differentiated DA neurons and not in undifferentiated cells.
(y)Electrophysiological analysis showed presence of action potentials in cells at Stage 3. In DA neurons from hES-LMX1A, a change in
the frequency of action potentials could be observed when DA was added to the medium; no change was detected in the neurons
from mock-hESC. In all experiments, n=3. *p<0.05. Scale bar=50lm. Color images available online at www.liebertonline.com/hum
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stained positive for FOXA2, coexpressed the A9-subtype
marker GIRK2, and were mature, as judged by coexpression
of DA transporter (DAT) (Fig. 4k–p). In contrast, DA neurons
differentiated from hES-LMX1A cells did not express the
A10-subtype marker calbindin, although some calbindin-
expressing neurons were observed, whereas this marker was
frequently coexpressed in mock-hESC-derived DA neurons
(Fig. 4r and s). DA neurons differentiated from either hES-
LMX1A cells or mock-hESC did not express the marker of
adrenergic neurons dopamine-b-hydroxylase (DBH, Fig. 4t
and u), or serotonin (5-HT), marker of serotonergic neurons
(Fig. 4v and w).
Functional characterization of DA neurons
differentiated from hES-LMX1A cells
We next tested whether DA neurons allowed to differ-
entiate fully in vitro (end of Stage 3) displayed the func-
tional characteristics expected from bona fide DA neurons.
For this purpose, we analyzed their ability to release DA in
response to appropriate stimuli. Cells differentiated from
either hES-LMX1A or mock-hESC (but not undifferentiated
cells) showed robust DA release induced by a depolarizing
solution of KCl (60 mM; see Fig. 4x). Next, we analyzed the
electrophysiological properties of DA neurons through ex-
tracellular recordings using the E2 Technology, in which
10–50 axons grow within a microchannel and allow si-
multaneous recording of multiple neurons (Morales et al.,
2008). These studies showed that cells differentiated from
either hES-LMX1A or mock-hESC, but not undifferentiated
cells, fired spontaneous action potentials, providing evi-
dence that these cells are, indeed, functional neurons.
Moreover, cells differentiated from hES-LMX1A, but not
from mock-hESC, responded to the application of DA with
a marked reduction in spontaneous firing activity (Fig. 4y),
a behavior characteristic of midbrain DA neurons (Friling
et al., 2009). Taken together, our results so far show that
clones of hESC engineered to overexpress LMX1A in neural
precursors, when subject to our optimized protocol for DA
neuron differentiation, efficiently generate DA neurons that
are molecularly and functionally of the ventral midbrain A9
subtype.
To investigate the functional properties of DA neurons
differentiated from hES-LMX1A and mock-hESC, we first
tested their ability to engraft and survive within the context
of the adult brain. For this purpose, we transplanted 2 · 105
differentiating hESC at mid-Stage 3 (after 2 weeks of cocul-
ture with PA6 cells) directly into the striatum of unlesioned
mice. One month after transplantation, grafted cells identi-
fied by GFP expression (Fig. 5a), immunofluorescence
against TUJ1/TH (Fig. 5b), and antibodies against human
nuclear antigen (HNA) (Fig. 5c) were found at the expected
position in 10 of 11 mice. To analyze longer grafting times,
we retained four mice injected with mock-hESC and four
mice injected with hES-LMX1A cells for an additional 4
months. In all eight animals, we found viable grafts con-
taining human TH-positive cells (Fig. 5d–f), although their
numbers were much higher in those injected with hES-
LMX1A cells (compare Fig. 5e and f). Moreover, confocal
immunofluorescence microscopy showed that the vast
majority of TH-positive cells found in the engrafted hES-
LMX1A cells 5 months after transplantation were mature A9-
subtype DA neurons, as shown by coexpression of GIRK2
and DAT (Fig. 5g). Consistent with this, we did not detect
GABAergic or serotonergic neurons in the grafted area (Fig.
5h and i).
Effect of LMX1A overexpression on DA neuron
differentiation of iPSC
We next tested whether the strategy of overexpressing
LMX1A under the neural NESTIN enhancer could promote
appropriate DA neuron differentiation from human iPSC.
For this purpose, we transduced iPSC with LV.NES.LM-
X1A.GFP or with control LVs. LMX1A overexpression was
verified at the protein level by immunofluorescence at Stage
2 (Fig. 6a and g). Neuronal and DA neuron differentiation
were evaluated at the end of Stage 3 by immunofluorescence
analyses against TUJ1 and TH, respectively (Fig. 6b–e and h–
k), and the maturation state of DA neurons by DAT ex-
pression (Fig. 6f and l). In addition to this, we followed by
quantitative RT-PCR the expression of the pluripotency-
associated gene NANOG, and those of the DA neuron dif-
ferentiation markers NURR1, EN1, and TH (Fig. 6m and p).
Overall, the results of these analyses were very similar to
those of hESC and showed that overexpression of LMX1A
did not significantly change the percentage of neurons dif-
ferentiated from iPSC, but dramatically increased the pro-
portion of neurons that are coaxed toward a DA neuron fate
(Fig. 6q). Moreover, the presence of synaptic proteins such as
synaptophysin was detected in discrete puncta that coloca-
lized with TH immunoreactivity (Fig. 6r), suggesting the
establishment of DA synaptic terminals. Finally, analyses of
DA release confirmed the functionality of DA neurons dif-
ferentiated from iPSC overexpressing LMX1A (Fig. 6s).
Discussion
One of the major bottlenecks to the development of hESC/
iPSC-based strategies for modeling and treating human
disease is the relative lack of efficient directed differentiation
protocols for generating the specific cell type(s) relevant to
the disease. In the case of PD, a variety of protocols have
been described that promote the differentiation of hESC/
iPSC toward DA neurons (for review, see Hwang et al., 2010),
but in most cases these were not appropriately patterned as
A9-subtype ventral midbrain DA neurons, the relevant cell
type for PD. Forcing the expression of patterning- and/or
fate-associated transcription factors may help overcome this
limitation, as evidenced by studies in which Lmx1a (An-
dersson et al., 2006; Friling et al., 2009) or a combination of
Nurr1 and Pitx3 (Martinat et al., 2006) or Nurr1 and Foxa2
(Lee et al., 2010) was overexpressed in mouse neural pre-
cursor cells. Here, we decided to focus on LMX1A, because it
was the only transcription factor the overexpression of which
had been shown to clearly increase the percentage of ventral
midbrain DA neurons differentiated from human neural
progenitors (Friling et al., 2009). In this latter work, hESC-
derived neural progenitors were transduced with LVs ex-
pressing Lmx1a under a constitutive PGK promoter. Building
on these data, we decided to exploit the ability of LVs to
provide long-term and robust transgene expression in plu-
ripotent stem cells and neural progenitors (Lois et al., 2002;
Pfeifer et al., 2002; Ma et al., 2003; Consiglio et al., 2004), as well
as the selectivity of expression in neural progenitor cells
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conferred by the neural NESTIN enhancer (Lothian and
Lendahl, 1997; Andersson et al., 2006), to address whether: (1)
human pluripotent stem cells can be stably engineered to
express LMX1A while maintaining their characteristic self-
renewal and pluripotent differentiation abilities; and (2) ex-
pression of LMX1A in the context of engineered hESC/iPSC is
sufficient to direct the fate of differentiating neural progenitors
toward ventral midbrain DA neurons of the A9 subtype.
On the first issue, our results show that clonal lines of
hESC containing one or two copies of the integrated LMX1A-
expressing LVs retain the typical features of nonmanipulated
hESC, including colony morphology and growth character-
istics, long-term self-renewing ability while maintaining a
stable karyotype, expression of pluripotency-associated
transcription factors and surface markers, in vitro differenti-
ation into derivatives of the three main embryo germ layers,
and teratoma formation ability (Fig. 3). This is particularly
important because, even though we confirmed the specificity
of expression of the neural NESTIN enhancer in neural pro-
genitors (Fig. 2), there was measurable expression of trans-
genic LMX1A in undifferentiated hESC (Fig. 4a), probably
owing to leakage of our system. Therefore, it is important to
note that the somewhat higher levels of LMX1A expression
in undifferentiated hES-LMX1A cells, compared with mock-
hESC, do not appear to be detrimental for their maintenance
as undifferentiated, pluripotent stem cells, even upon long-
term passaging.
However, when induced to differentiate toward neuronal
fates, hES-LMX1A cells generated significantly higher num-
bers of DA neurons than mock-hESC (*40% more, based on
TH/TUJ1 double staining) and, more importantly, most of
these DA neurons were of the ventral midbrain A9 subtype
(up to 75% of them, compared with *25% in the case of
mock-hESC, based on colabeling of TH and GIRK2). Con-
sequently, of 100 hES-LMX1A cells, we obtained > 30 A9-
subtype DA neurons, versus approximately seven from
FIG. 5. Functional characterization of the DA neurons generated. (a) Section of the brain 1 month after transplantation of
cells transduced with LV.PGK.GFP showing engraftment and survival of the infected cells. (Inset) Presence of GFP-positive
cells in the injected area. (b, c) Analysis of mouse brain 4 weeks after receiving transplantation of hES-LMX1A (clone D) at
Stage 3. (b) Grafted cells stain positive for TUJ1 and TH. (c) The neurons (TUJ1-positive cells) within the graft area show HNA
staining, indicating their human origin. (d–i) Sections of mouse brains 5 months after transplantation of mock-hESC and hES-
LMX1A (clone D) at Stage 3. Grafted dopaminergic cells are of human origin, as judged by HNA staining (d), and survive in
the host mouse brain 5 months after transplantation of mock-hESC (e), and in much larger numbers after transplantation of
hES-LMX1A cells (f). (g) hES-LMX1A cells are able to differentiate toward midbrain DA neurons in vivo 5 months after
transplantation. Immunostaning for TUJ1, TH, GIRK2, and DAT in the contralateral side shows the typical staining of
dopaminergic fibers in the intact striatum. In the injected side, newly generated midbrain DA neurons that are TH-, DAT-,
GIRK2-positive could be observed. (h, i) Absence of GABAergic neurons (GAD-positive cells; h) and serotonergic neurons (5-
HT-positive cells; i) in the transplanted area. Scale bar= 50 lm.
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mock-hESC, that is, close to a fivefold increase in the overall
yield of the differentiation procedure. These differences
are consistent with more differentiating cells being recruited
into the ventral midbrain DA neuron lineage as transgenic
LMX1A begins to be expressed in neural precursors, as evi-
denced by the increased numbers of LMX1A-positive cells in
Stage 2 of differentiation.
Our results show that, under ventralizing conditions such
as exposure to SHH, LMX1A is sufficient to direct the dif-
ferentiation of human neural progenitors toward ventral
midbrain DA neurons. This is in agreement with previous
studies in the mouse, conducted by the Ericson laboratory
(Andersson et al., 2006; Friling et al., 2009), and also in human
cells (Friling et al., 2009). Therefore, the reported failure of
other groups to induce human DA neuron differentiation by
overexpressing LMX1A (Roybon et al., 2008; Cai et al., 2009)
is likely the result of inadequate levels of expression of this
factor, due either to low transfection efficiency (Cai et al.,
2009) or to strong overexpression driven by retroviruses
(Roybon et al., 2008). In this regard, it is important to note
that the levels of LMX1A expression achieved in our clonal
hES-LMX1A cell lines harboring one or two LV integrations
are in the same range of endogenous LMX1A expression
levels during DA differentiation. Thus, LMX1A expression in
hES-LMX1A cells, at its peak in mid-Stage 3, is roughly only
three times higher than that of mock-hESC (Fig. 4a). Taking
FIG. 6. LMX1A enhances generation of midbrain DA neurons in iPSC. (a, g) NPCs from iPS.NES.LMX1A.GFP contain more
LMX1A-positive cells than those from iPS.NES.GFP. (b, h) Cells at Stage 3 coexpressed TUJ1 and TH. Higher magnification
images (c–e, i–k) showed extensive presence of TH-positive cells in iPS.NES.LMX1A.GFP compared with iPS.NES.GFP. (f, l) TH
and DAT immunocytochemistry performed at the same stage of differentiation. (m) qPCR analysis presenting a decrease in the
expression levels of NANOG as the differentiation occurred in both lines. Higher levels of expression of NURR1 (n) and EN1 (o)
are evident in iPS.NES.LMX1A.GFP than in iPS.NES.GFP. (p) Markedly higher expression of TH in iPS.NES.LMX1A.GFP
in relation to iPS.NES.GFP. (q) Quantification of the neuronal and dopaminergic yield at Stage 3. The staining of TUJ1 is *55%
in both lines. Approximately 40% of the neurons are labeled with TH in iPS.NES.GFP, and this value increases to 65% in
iPS.NES.LMX1A.GFP. (r) Immunocytochemical analysis for the presynaptic-specific marker synaptophysin (SYP, red channel)
and TH (green channel); the area indicated with an arrowhead is shown in the inset at higher magnification. (s) Release of DA
after treatment with high potassium concentration is found in differentiated DA neurons from iPS.NES.LMX1A.GFP. In all
experiments, n= 3. *p< 0.05. Scale bar= 50lm. Color images available online at www.liebertonline.com/hum
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into account that, as discussed above, the number of cells
undergoing A9 DA neuron differentiation is about five times
higher in hES-LMX1A cells than in mock-hESC, it follows
that the levels of LMX1A expression per cell should be within
the same order of magnitude in either case.
Our results also show that hES-LMX1A cells committed to
DA lineages in vitro are able to complete differentiation to A9
ventral midbrain DA neurons upon grafting into the adult
mouse brain. We transplanted differentiating cells at mid-Stage 3
(after 2 weeks of coculture with PA6 cells), because we surmised
that cells at this stage of differentiation, at which they express
high levels of NURR1, EN1, ALDH1A1, and TH (see Fig. 4c–f),
would have become depleted of undifferentiated progenitors
but were not yet fully differentiated, thus making them more
likely to survive after grafting. Indeed, viable grafted cells were
recovered 5 months after transplantation and shown to have
completed differentiation in situ. Conversely, mock-hESC pre-
treated in vitro under the same conditions and transplanted into
adult mouse brains differentiated very poorly in vivo, in agree-
ment with previous reports that highlighted the inability of adult
brain tissue to direct transplanted human neural progenitors to
acquire the DA neuron fate (Ben-Hur et al., 2004). Therefore, in
the absence of appropriate environmental cues, transgenic
LMX1A expression appears to maintain a ventral midbrain DA
neuron differentiation program in hES-LMX1A cells.
Our strategy of LV-mediated engineering of human plu-
ripotent stem cells to overexpress LMX1A in neural pro-
genitors provides an efficient way to generate enriched
populations of neurons with the characteristics of A9 ventral
midbrain DA neurons. As this strategy is applicable to both
hESC and iPSC, it should be suitable for modeling PD
pathogenesis in vitro, as well as worth considering when
designing future cell-therapy applications for this disease.
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